Tissue factor proangiogenic signaling in cancer progression

doi:10.1016/S0049-3848(12)70032-4

Thrombosis Research

Volume 129, Supplement 1, April 2012, Pages S127-S131

https://doi.org/10.1016/S0049-3848(12)70032-4 Get rights and content

Abstract

Cancer progression from a dormant, non-vascularized benign tumor to metastatic disease is a multiple steps process that critically depends on contributions from the hemostatic system. Tissue factor (TF), protease activated receptors (PARs), factor VIIa, and the endothelial protein C receptor (EPCR) are expressed by tumor cells as well as the host compartment. These components of the hemostatic system regulate tumor growth, angiogenesis and metastasis. Here we review the evidence that TF-dependent signaling is the major driver of primary tumor growth, whereas TF-initiated coagulation and interactions of procoagulant tumor cells with the host compartments initiate multiple pathways that support and regulate the efficiency of metastatic tumor dissemination.

References (77)

JS Palumbo et al.
Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms
Blood
(2007)
E Camerer et al.
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis
Blood
(2004)
ML Nierodzik et al.
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype
Cancer Cell
(2006)
GL Van Sluis et al.
Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation
Cancer Lett
(2011)
NA Horowitz et al.
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain
Blood
(2011)
GL Van Sluis et al.
Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement
Blood
(2009)
M Bezuhly et al.
Role of activated protein C and its receptor in inhibition of tumor metastasis
Blood
(2009)
M Shipitsin et al.
Molecular definition of breast tumor heterogeneity
Cancer Cell
(2007)
LM Beaulieu et al.
Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1
Exp Cell Res
(2007)
C Feistritzer et al.
Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation
Blood
(2005)

JH Finigan et al.

Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation

J Biol Chem

(2005)

GL Van Sluis et al.

The role of activated protein C in cancer progression

Thromb Res

(2010)

S Sabrkhany et al.

The role of blood platelets in tumor angiogenesis

Biochim Biophys Acta

(2011)

B Shao et al.

Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome

Blood

(2011)

H Laubli et al.

Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes

Blood

(2009)

EM Conn et al.

Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation

J Biol Chem

(2008)

M Labelle et al.

Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes Metastasis

Cancer Cell

(2011)

JL Yu et al.

Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis

Blood

(2005)

W Ruf et al.

Tissue factor and cell signalling in cancer progression and thrombosis

J Thromb Haemost

(2011)

N Magnus et al.

Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells

Blood

(2010)

GM Hjortoe et al.

Tissue factor-factor VIIa specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated via PAR-2 and results in increased cell migration

Blood

(2004)

T Albrektsen et al.

Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells

J Thromb Haemost

(2007)

HH Versteeg et al.

Inhibition of tissue factor signaling suppresses tumor growth

Blood

(2008)

Y Liu et al.

Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways

Biochem Biophys Res Commun

(2006)

TC Carneiro-Lobo et al.

Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model

J Thromb Haemost

(2009)

F Gessler et al.

Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells

Neuroscience

(2010)

F Schaffner et al.

Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development

Blood

(2010)

C Fischer et al.

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Cell

(2007)

Y Saito et al.

The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody

Eur J Cancer

(2011)

BM Mueller et al.

Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis

Proc Natl Acad Sci USA

(1992)

ME Bromberg et al.

Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation

Proc Natl Acad Sci USA

(1995)

BM Mueller et al.

Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis

J Clin Invest

(1998)

A Amirkhosravi et al.

Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma

Thromb Haemost

(2002)

J Zhao et al.

rNAPc2 inhibits colorectal cancer in mice through tissue factor

Clin Cancer Res

(2009)

X Wang et al.

Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice

Int J Cancer

(2004)

N Esumi et al.

Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor

Cancer Res

(1991)

B Nieswandt et al.

Lysis of tumor cells by natural killer cells in mice is impeded by platelets

Cancer Res

(1999)

JS Palumbo et al.

Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer-mediated elimination of tumor cells

Blood

(2004)

Cited by (30)

Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids)
2020, Recent Advances in Natural Products Analysis
Alkaloids are a large cluster of molecules found in Mother Nature all over the world. They are all secondary compounds and collection of miscellaneous elements and biomolecules, derived from amino acids or from transamination. This diverse chemical group is categorized, based on the amino acids that deliver their nitrogen atom and part of their skeleton. Alkaloids from a similar origin or having the same basic nucleus may have dissimilar biosynthetic pathways and different biological activity. They are derived from l-phenylalanine, l-tyrosine, anthranilic acid or acetate, l-histidine, l-ornithine, nicotinic acid, and l-lysine. Apart from other types of alkaloids, indole, tropane, and isoquinoline alkaloids are very important. People from all over the world are using them in their everyday life. Alkaloids can also have an animal origin, which may be endogenous or exogenous. This chapter highlights the phytochemistry of the main representatives among the diverse group of alkaloids. This chapter also focuses on their extraction, purification, fractionation, identification, and quantification procedures. A fundamental understanding of the biological activity of important alkaloids is also highlighted in this chapter. With the potential of revealing new compounds and diverse pharmacological properties, alkaloids still embrace a great potential for the future of drug discovery.
Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour
2020, Biochimica et Biophysica Acta - Reviews on Cancer
Venous thromboembolism (VTE) is a common cardiovascular disease thought to be the outcome of an intricate interplay between acquired and inherited factors that act together to modify disease risk. Over the years, several single-nucleotide polymorphisms (SNPs) in candidate genes have been associated with disease risk, including F5 rs6025, F2 rs1799963, FGG rs2066865, ABO genetic variants, among others less common. More recently, genome-wide association studies (GWAS) have contributed to the identification of novel VTE-associated SNPs, some of them located in novel genes with no clear role in the haemostatic system, such as SLC44A2 rs2288904 and TSPAN15 rs78707713. Given the existence of a tight relationship between VTE and cancer, with both pathologies sharing biological pathways that allow one to promote the other, these SNPs constitute potential prognostic and predictive biomarkers currently needed for better management of cancer patients. Among solid tumours, ovarian cancer (OC) is one of the most frequently associated with VTE. Indeed, haemostatic components might have a significant impact in OC progression, and therefore, the clinical and biological implications of VTE-associated SNPs should be assessed in patients with this neoplasia.
Mechanisms coupling thrombin to metastasis and tumorigenesis
2018, Thrombosis Research
Citation Excerpt :
TF has been linked to regulation of signaling functions through mechanisms directly involving the TF cytoplasmic domain, as well as through regulation of signaling events coupled to protease activated receptor-2, and integrins [14,17,19]. These signaling mechanisms have been shown to support tumor cell invasion, tumor growth, and angiogenesis [14,17,19]. Certainly, the potential for TF-mediated signaling events to promote tumor invasion and angiogenesis would be expected to drive metastatic potential.
The association of malignancy and thrombophilia is bidirectional, as evidenced by four decades of studies in animal models showing that hemostatic system components support cancer progression. Consistent with this view, clinical studies have suggested that anticoagulants not only limit thromboembolic complications associated with cancer, but also improve survival by impeding cancer progression, and may even prevent the development of cancer. In order to fully capitalize on this association, a detailed understanding of the mechanisms coupling hemostatic factors to cancer pathogenesis is required. Multiple studies have shown that thrombin-mediated procoagulant functions strongly promote metastatic potential. In particular, the platelet/fibrin(ogen) axis has been shown to protect newly formed micrometastases from innate immune surveillance, contribute to creation of a metastatic niche by recruitment of prometastatic inflammatory cells, and promote the epithelial to mesenchymal transition of metastatic cells. Thrombin-mediated functions have also been shown to support tumor growth in some contexts, and have even been linked to tumorigenesis in the setting of inflammation-driven colon cancer. Here, local thrombin-mediated extravascular fibrin deposition, and specifically fibrin-α_Mβ₂ integrin interaction, push intestinal inflammatory cells toward a pro-tumorigenic phenotype, resulting in the elaboration of key cytokines and growth factors that support the proliferation and survival of transformed intestinal epithelial cells. These studies reveal that hemostatic factors can serve as a bridge between pathological inflammation and the development of cancer. As a large proportion of cancers are caused by pathological inflammation, these studies suggest that therapies targeting the nexus between hemostasis and inflammation could be used to prevent cancer development.
Protein kinases that phosphorylate splicing factors: Roles in cancer development, progression and possible therapeutic options
2017, International Journal of Biochemistry and Cell Biology
Citation Excerpt :
The representative dichloroindolyl enaminonitrile KH-CB19 is a powerful (IC50 = 20 nM) and highly selective inhibitor of CLK1 and CLK4, with reduced affinity to CLK2 and CLK3. Treatment of microvascular endothelial cells with 10 μM KH-CB19 results in inhibition of SRSF3, SRSF4, and SRSF6 and affects splicing of Tissue Factor (TF) (Fedorov et al., 2011), a protein crucial for tumor angiogenesis and metastatic spread (Schaffner et al., 2012). Treatment of lung cancer cells with KH-CB19 attenuates their ability to simulate hypoxic angiogenesis (Eisenreich et al., 2013; Fedorov et al., 2011).
Disturbed alternative splicing is a common feature of human tumors. Splicing factors that control alternative splicing are phosphorylated by multiple kinases, including these that specifically add phosphoryl groups to serine-arginine rich proteins (e.g. SR-protein kinases, cdc2-like kinases, topoisomerase 1), and protein kinases that govern key cellular signaling pathways (i.e. AKT). Phosphorylation of splicing factors regulates their subcellular localization and interactions with target transcripts and protein partners, and thus significantly contributes the final result of splicing reactions.
In this review we aim to summarize the current knowledge on the role of splicing kinases in cancer. Published studies and recently released data of The Cancer Genome Atlas demonstrate that expressions and activities of splicing kinases are commonly disturbed in cancers. Aberrant functioning of splicing kinases results in changed alternative splicing of tumor suppressors (e.g. p53) and regulators of cell signaling (e.g. MAPKs), apoptosis (e.g. MCL), and angiogenesis (VEGF). Splicing kinases act in complicated regulatory networks in which they mutually affect each other’s activity to provide tight control of cellular signaling. Dysregulation of these regulatory networks contributes to oncogenic transformation, uncontrolled proliferation, enhanced migration and invasion. Furthermore, the activities of splicing kinases significantly contribute to cellular responses to genotoxic stress.
In conclusion, published data provide strong evidence that splicing kinases emerge as important regulators of key processes governing malignant transformation, progression, and response to therapeutic treatments, suggesting their potential as clinically relevant targets.
Interface between Thrombosis, Inflammation, and Angiogenesis in Cancer Progression
2016, Anti-Angiogenesis Strategies in Cancer Therapies
The degree of cancer-associated thrombosis correlates with the clinical progression of cancer. Investigations have clarified the molecular pathways utilized by the cancer cells to interact with the hemostatic system to promote cancer progression. Cancer cells express tissue factor (TF), a principal initiator of blood coagulation; the expression levels of TF correlate with tumor progression. The binary (TF-VIIa or TF-Xa) or ternary (TF-VIIa-Xa) complexes of TF, in addition to triggering hypercoagulation, also initiate cell signaling in cancer cells via protease activated-receptors (PARs). These signaling events may occur prior to or independent of coagulation activation. TF-mediated signaling events lead to regulation of angiogenesis, tumor growth, metastasis, and inflammation. In this chapter, the signaling events downstream of TF-VIIa-Xa-PAR2 are discussed in the context of thrombosis, angiogenesis, and inflammation.
Vascular complications in glioma patients
2016, Handbook of Clinical Neurology
Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, the role of anticoagulants as anticancer therapy, and vascular complications such as ischemic stroke and intracranial bleeding. The coagulation cascade is intimately involved in cancer-related thrombosis, glioma progression, and vascular complications of glioma therapy. Tissue factor is the principal initiator of coagulation and is upregulated in a glioma subtype-specific fashion. Short-term (perioperative) antithrombotic prophylaxis is effective, but long-term anticoagulation, although attractive, is not routinely indicated. Most patients with symptomatic venous thromboembolism can be safely anticoagulated, including those on anti-vascular endothelial growth factor therapeutics such as bevacizumab. Initial therapy should include low-molecular-weight heparin, and protracted anticoagulant treatment, perhaps indefinitely, is indicated. Many complex interactions resulting in vessel wall injury can lead to ischemic stroke, intracranial and intratumoral hemorrhage, and long-term sequelae such as cognitive impairment.

View all citing articles on Scopus

View full text

Tissue factor proangiogenic signaling in cancer progression

Abstract

Blood

Blood

Cancer Cell

Cancer Lett

Blood

Blood

Blood

Cancer Cell

Exp Cell Res

Blood

J Biol Chem

Thromb Res

Biochim Biophys Acta

Blood

Blood

J Biol Chem

Cancer Cell

Blood

J Thromb Haemost

Blood

Blood

J Thromb Haemost

Blood

Biochem Biophys Res Commun

J Thromb Haemost

Neuroscience

Blood

Cell

Eur J Cancer

Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis

Proc Natl Acad Sci USA

Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation

Proc Natl Acad Sci USA

Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis

J Clin Invest

Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma

Thromb Haemost

rNAPc2 inhibits colorectal cancer in mice through tissue factor

Clin Cancer Res

Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice

Int J Cancer

Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor

Cancer Res

Lysis of tumor cells by natural killer cells in mice is impeded by platelets

Cancer Res

Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer-mediated elimination of tumor cells

Blood